

**MONTREAL PROTOCOL
ON SUBSTANCES THAT DEplete
THE OZONE LAYER**



UNEP

**2002 REPORT OF THE
AEROSOLS, STERILANTS, MISCELLANEOUS USES AND
CARBON TETRACHLORIDE
TECHNICAL OPTIONS COMMITTEE**

2002 Assessment

Montreal Protocol on Substances that Deplete the Ozone Layer

**United Nations Environment Programme (UNEP)
2002 Report of the Aerosols, Sterilants, Miscellaneous Uses and
Carbon Tetrachloride Technical Options Committee**

2002 Assessment

The text of this report is composed in Times New Roman.

Coordination: Aerosols, Sterilants, Miscellaneous Uses and Carbon
Tetrachloride Technical Options Committee

Composition and layout: Helen Tope

Reproduction: UNEP/ Ozone Secretariat, Nairobi
Date:

Under certain conditions, printed copies of this report are available from:

United Nations Environment Programme
Ozone Secretariat
P.O. Box 30552
Nairobi, Kenya

This document is also available in portable document format from:

<http://www.teap.org>

No copyright involved. This publication may be freely copied, abstracted and cited, with acknowledgement of the source of the material.

ISBN 92-807-2289-1

Disclaimer

The United Nations Environment Programme (UNEP), the Technology and Economic Assessment Panel (TEAP) Co-chairs and members, the Technical Options Committee Chairs, Co-chairs and members, the TEAP Task Forces Co-chairs and members, and the companies and organisations that employ them do not endorse the performance, worker safety, or environmental acceptability of any of the technical options discussed. Every industrial operation requires consideration of worker safety and proper disposal of contaminants and waste products. Moreover, as work continues – including additional toxicity evaluation – more information on health, environmental and safety effects of alternatives and replacements will become available for use in selecting among the options discussed in this document.

UNEP, the TEAP Co-chairs and members, the Technical Options Committee Chairs, Co-chairs and members, and the Technology and Economic Assessment Panel Task Forces Co-chairs and members, in furnishing or distributing this information, do not make any warranty or representation, either express or implied, with respect to the accuracy, completeness, or utility; nor do they assume any liability of any kind whatsoever resulting from the use or reliance upon any information, material or procedure contained herein, including but not limited to any claims regarding health, safety, environmental effect or fate, efficacy, or performance, made by the source of information.

Mention of any company, association, or product in this document is for information purposes only and does not constitute a recommendation of any such company, association, or product, either express or implied by UNEP, the Technology and Economic Assessment Panel co-chairs or members, the Technical and Economic Options Committee Chairs, Co-chairs or members, the TEAP Task Forces Co-chairs or members or the companies or organisations that employ them.

Acknowledgement

The Technology and Economic Assessment Panel, its Technical Options Committees and the Task Forces Co-chairs and members acknowledge with thanks the outstanding contributions from all of the individuals and organisations who provided support to Panel, Committees and Task Forces Co-chairs and members. The opinions expressed are those of the Panel, the Committees and Task Forces and do not necessarily reflect the views of any sponsoring or supporting organisation.

**UNEP
2002 REPORT OF THE
AEROSOLS, STERILANTS,
MISCELLANEOUS USES AND
CARBON TETRACHLORIDE
TECHNICAL OPTIONS COMMITTEE**

2002 ASSESSMENT

	TABLE OF CONTENTS	PAGE
ES	EXECUTIVE SUMMARY	1
ES.1	AEROSOL PRODUCTS (OTHER THAN MDIs).....	1
ES.2	METERED DOSE INHALERS	3
ES.3	STERILANTS.....	6
ES.4	MISCELLANEOUS USES	7
ES.5	LABORATORY AND ANALYTICAL USES	7
ES.6	CARBON TETRACHLORIDE	9
1.	INTRODUCTION	11
1.1	THE MONTREAL PROTOCOL INCLUDING ISSUES RELATED TO THE AEROSOLS, STERILANTS, MISCELLANEOUS USES AND CARBON TETRACHLORIDE TECHNICAL OPTIONS COMMITTEE	11
1.2	THE TECHNOLOGY AND ECONOMIC ASSESSMENT PANEL	13
1.3	THE TEAP AEROSOLS, STERILANTS, MISCELLANEOUS USES AND CARBON TETRACHLORIDE TECHNICAL OPTIONS COMMITTEE AND THE 2002 ASSESSMENT	13
2.	AEROSOLS	17
2.1	WORLDWIDE USE OF CFCs IN AEROSOL PRODUCTS (OTHER THAN METERED DOSE INHALERS)	17
2.2	ALTERNATIVES TO CFCs IN AEROSOLS.....	19
2.2.1	<i>Currently available alternatives</i>	19
2.2.2	<i>Hydrocarbons</i>	21
2.2.3	<i>Dimethyl ether</i>	23
2.2.4	<i>Hydrochlorofluorocarbons and hydrofluorocarbons</i>	23
2.2.5	<i>Compressed gases</i>	24
2.2.6	<i>Solvent reformulation</i>	25
2.2.7	<i>Alternative non-aerosol methods</i>	26
2.3	APPLICATIONS WITH POTENTIAL CHALLENGES IN REFORMULATION	27
2.3.1	<i>Pharmaceutical products (other than MDIs)</i>	27
2.3.2	<i>Industrial and technical specialities</i>	27
2.4	ISSUES FOR ARTICLE 5(1) COUNTRIES AND CEIT	28
3.	METERED DOSE INHALERS.....	29
3.1	INTRODUCTION TO LUNG DISEASES, EPIDEMIOLOGY, TREATMENT OPTIONS AND MEDICAL TRENDS	29
3.1.1	<i>Asthma</i>	29
3.1.2	<i>Chronic obstructive pulmonary disease</i>	30
3.1.3	<i>Treatment</i>	31
3.2	METERED DOSE INHALERS	34
3.2.1	<i>What is a metered dose inhaler?</i>	34
3.2.2	<i>Trends in CFC consumption</i>	35
3.3	ALTERNATIVES TO CFC MDIs	38
3.3.1	<i>MDI products using HFCs and other non-CFC propellants</i>	38
3.3.2	<i>Dry powder inhalers</i>	40
3.3.3	<i>Nebulisers</i>	42
3.3.4	<i>Oral medication</i>	43
3.3.5	<i>Injectable therapy</i>	44
3.3.6	<i>Commercial availability of alternatives</i>	45
3.3.7	<i>Clinical and regulatory requirements</i>	46
3.4	TRANSITION TO ALTERNATIVES TO CFC MDIs.....	47

3.4.1	Overview	47
3.4.2	Transition strategies.....	49
3.4.3	Experiences in transition.....	50
3.4.4	Anticipated phase-out	51
3.4.5	Potential barriers to CFC MDI phase-out.....	52
3.4.6	Education and training	53
3.5	MANAGING THE PHASE-OUT OF CFC MANUFACTURING.....	54
3.5.1	CFC production for CFC MDI manufacture.....	54
3.5.2	Future CFC requirements	55
3.5.3	Use of recycled CFCs.....	56
3.5.4	Stockpiling CFCs	56
3.6	ISSUES FOR ARTICLE 5(1) COUNTRIES AND CEIT	58
3.6.1	Current situation in Article 5(1) countries and CEIT	58
3.6.2	Manufacturing issues – CFC production and MDI production	60
3.6.3	Technology transfer, local production and costs	61
3.6.4	Conclusions.....	62
4.	STERILANTS	65
4.1	INTRODUCTION	65
4.2	CFC AND HCFC USE FOR STERILISATION WORLDWIDE	66
4.3	AVAILABLE OPTIONS FOR REPLACING CFC-12.....	66
4.4	CONCLUSIONS	68
5.	MISCELLANEOUS USES	69
5.1	TOBACCO EXPANSION.....	69
5.1.1	Background	70
5.1.2	Alternative expansion.....	70
5.1.3	Costs.....	71
5.1.4	Developing country perspective	71
5.2	FOOD FREEZANTS	72
5.3	LEAK DETECTION.....	72
5.4	REPAIR OF PIPING.....	72
5.5	SOLAR TRACKING SYSTEMS	73
5.6	WIND TUNNELS.....	73
5.7	THERMOSTATS AND THERMOMETERS.....	73
5.8	LINEAR ACCELERATORS	74
5.9	OTHER MISCELLANEOUS USES	74
6.	LABORATORY AND ANALYTICAL USES.....	75
6.1	INTRODUCTION	75
6.2	THE USE OF CONTROLLED SUBSTANCES FOR LABORATORY AND ANALYTICAL USES	

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_11851

